Literature DB >> 32714521

Management of Hepatitis C in Special Populations: HIV Coinfection, Renal Disease, and Decompensated Cirrhosis.

Joseph K Lim1.   

Abstract

Answer questions and earn CME.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID： 32714521      PMCID： PMC7373776          DOI： 10.1002/cld.965

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  9 in total

Review 1.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

Review 2.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-12-16

3.  International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.

Authors:  Norah A Terrault; Geoff W McCaughan; Michael P Curry; Edward Gane; Stefano Fagiuoli; James Y Y Fung; Kosh Agarwal; Les Lilly; Simone I Strasser; Kimberly A Brown; Adrian Gadano; Paul Y Kwo; Patrizia Burra; Didier Samuel; Michael Charlton; Mario G Pessoa; Marina Berenguer
Journal:  Transplantation       Date:  2017-05       Impact factor: 4.939

4.  Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Authors:  Sergio M Borgia; Janet Dearden; Eric M Yoshida; Stephen D Shafran; Ashley Brown; Ziv Ben-Ari; Matthew E Cramp; Curtis Cooper; Matthew Foxton; Conrado Fernandez Rodriguez; Rafael Esteban; Robert Hyland; Sophia Lu; Brian J Kirby; Amy Meng; Svetlana Markova; Hadas Dvory-Sobol; Anu O Osinusi; Rafael Bruck; Javier Ampuero; Stephen D Ryder; Kosh Agarwal; Raymond Fox; David Shaw; Shariq Haider; Bernard Willems; Yoav Lurie; Jose Luis Calleja; Edward J Gane
Journal:  J Hepatol       Date:  2019-06-11       Impact factor: 25.083

5.  Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.

Authors:  B Njei; T R McCarty; B E Fortune; J K Lim
Journal:  Aliment Pharmacol Ther       Date:  2016-09-19       Impact factor: 8.171

Review 6.  Hepatitis C virus and the kidney.

Authors:  Stanislas Pol; Lucia Parlati; Michel Jadoul
Journal:  Nat Rev Nephrol       Date:  2019-02       Impact factor: 28.314

7.  The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.

Authors:  Elliot B Tapper; Michael S Hughes; Maria Buti; Jean-Francois Dufour; Steve Flamm; Saima Firdoos; Michael P Curry; Nezam H Afdhal
Journal:  Transplantation       Date:  2017-05       Impact factor: 4.939

8.  Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Authors:  Vincent Lo Re; Michael J Kallan; Janet P Tate; A Russell Localio; Joseph K Lim; Matthew Bidwell Goetz; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Lesley Park; Robert Dubrow; K Rajender Reddy; Jay R Kostman; Brian L Strom; Amy C Justice
Journal:  Ann Intern Med       Date:  2014-03-18       Impact factor: 25.391

Review 9.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.